etodolac has been researched along with Neoplasms in 6 studies
Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).
etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compound 9 exhibited anticancer activity with an IC(50) value of 54 µM (22." | 1.39 | Synthesis, cytotoxicity, and pro-apoptosis activity of etodolac hydrazide derivatives as anticancer agents. ( Akbuğa, J; Bingöl-Özakpınar, Ö; Çevik, Ö; Çıkla, P; Küçükgüzel, ŞG; Özbaş-Turan, S; Özsavcı, D; Şahin, F; Şener, A, 2013) |
| "When tumors reached 100 mm, mice were treated with CpG-C/vehicle, and 24 hours later the tumor was excised along with P+E/vehicle treatment." | 1.37 | Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. ( Ben-Eliyahu, S; Benish, M; Goldfarb, Y; Levi, B; Melamed, R; Sorski, L, 2011) |
| "As part of our screening program for cancer inhibitory agents effective specifically in the promotion stage of cancer development, we have evaluated the possible inhibitory effects of 36 non-steroidal anti-inflammatory drugs (NSAIDs) on the Epstein-Barr virus early antigen (EBV-EA) activation which was induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in Raji cells." | 1.31 | Inhibition of epstein-barr virus early antigen activation promoted by 12-O-tetradecanoylphorbol-13-acetate by the non-steroidal anti-inflammatory drugs. ( Azuine, MA; Kapadia, GJ; Konoshima, T; Nishino, H; Takasaki, M; Takayasu, J; Tokuda, H, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Çıkla, P | 1 |
| Özsavcı, D | 1 |
| Bingöl-Özakpınar, Ö | 1 |
| Şener, A | 1 |
| Çevik, Ö | 1 |
| Özbaş-Turan, S | 1 |
| Akbuğa, J | 1 |
| Şahin, F | 1 |
| Küçükgüzel, ŞG | 1 |
| Goldfarb, Y | 1 |
| Sorski, L | 1 |
| Benish, M | 1 |
| Levi, B | 1 |
| Melamed, R | 1 |
| Ben-Eliyahu, S | 1 |
| Lu, D | 1 |
| Cottam, HB | 1 |
| Corr, M | 1 |
| Carson, DA | 1 |
| Kapadia, GJ | 1 |
| Azuine, MA | 1 |
| Takayasu, J | 1 |
| Konoshima, T | 1 |
| Takasaki, M | 1 |
| Nishino, H | 1 |
| Tokuda, H | 1 |
1 review available for etodolac and Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
5 other studies available for etodolac and Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Synthesis, cytotoxicity, and pro-apoptosis activity of etodolac hydrazide derivatives as anticancer agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line; Cell Line, Tumor; Dose-Response Rel | 2013 |
Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses.
Topics: Analysis of Variance; Animals; Chemotherapy, Adjuvant; Disease Models, Animal; Etodolac; Female; Imm | 2011 |
Repression of beta-catenin function in malignant cells by nonsteroidal antiinflammatory drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Cell Line, Tumor; Etodolac; Humans; Neoplasms | 2005 |
Inhibition of epstein-barr virus early antigen activation promoted by 12-O-tetradecanoylphorbol-13-acetate by the non-steroidal anti-inflammatory drugs.
Topics: Acetates; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Viral; Benzene; Carcinogens; Carcinoma; | 2000 |